(DBEZ) Xtrackers MSCI Eurozone - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US2330516970

European, Equities, Passive, Hedged, Currency

Description: DBEZ Xtrackers MSCI Eurozone

The Xtrackers MSCI Eurozone Hedged Equity ETF (DBEZ) employs a passive investment strategy to mirror the performance of its underlying index, which comprises equity securities from European Monetary Union countries. By doing so, it aims to shield investors from the impact of USD-EUR exchange rate fluctuations. The fund maintains a concentrated portfolio, investing at least 80% of its assets in the component securities of the underlying index, and is classified as non-diversified.

From a technical standpoint, the ETF has demonstrated a bullish trend, with its current price of $53.22 exceeding both its 20-day and 50-day simple moving averages (SMA20: $50.89, SMA50: $49.87). The 200-day simple moving average (SMA200: $47.39) further supports the notion of an uptrend. The average true range (ATR: 0.99) indicates a moderate level of volatility, equivalent to 1.86% of the current price. Given the 52-week high and low ($53.22 and $42.51, respectively), the ETF appears to be trading near its peak, suggesting potential resistance at this level.

Fundamentally, the ETFs assets under management (AUM) stand at $72.83M USD, indicating a relatively modest size. This could impact liquidity and potentially lead to higher trading costs. However, the ETFs focus on the Eurozone, a significant economic region, provides exposure to a diverse range of European companies.

Forecast: Based on the technical and fundamental data, a potential forecast for DBEZ is a continued upward trend, driven by the ongoing bull run in the Eurozone equities. However, the ETFs proximity to its 52-week high may lead to a consolidation phase or a slight correction. If the SMA20 and SMA50 continue to rise, and the ATR remains stable, it could be a buying opportunity. Conversely, a decline below the SMA50 could signal a reversal in the trend. Investors should closely monitor the ETFs price action and adjust their strategies accordingly.

Additional Sources for DBEZ ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

DBEZ ETF Overview

Market Cap in USD 75m
Category Europe Stock
TER 0.45%
IPO / Inception 2014-12-10

DBEZ ETF Ratings

Growth Rating 79.2
Fundamental -
Dividend Rating 7.61
Rel. Strength -1.05
Analysts -
Fair Price Momentum 50.53 USD
Fair Price DCF -

DBEZ Dividends

Dividend Yield 12m 0.53%
Yield on Cost 5y 0.93%
Annual Growth 5y -15.25%
Payout Consistency 84.1%
Payout Ratio %

DBEZ Growth Ratios

Growth Correlation 3m 72.3%
Growth Correlation 12m 81.7%
Growth Correlation 5y 90.8%
CAGR 5y 14.02%
CAGR/Max DD 5y 0.60
Sharpe Ratio 12m 1.08
Alpha 3.31
Beta 0.672
Volatility 12.82%
Current Volume 0.7k
Average Volume 20d 7.3k
What is the price of DBEZ shares?
As of July 04, 2025, the stock is trading at USD 51.21 with a total of 731 shares traded.
Over the past week, the price has changed by +1.49%, over one month by -0.42%, over three months by +8.99% and over the past year by +14.64%.
Is Xtrackers MSCI Eurozone a good stock to buy?
Yes. Based on ValueRay's Analyses, Xtrackers MSCI Eurozone (NYSE ARCA:DBEZ) is currently (July 2025) a good stock to buy. It has a ValueRay Growth Rating of 79.17 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DBEZ is around 50.53 USD . This means that DBEZ is currently overvalued and has a potential downside of -1.33%.
Is DBEZ a buy, sell or hold?
Xtrackers MSCI Eurozone has no consensus analysts rating.
What are the forecasts for DBEZ share price target?
According to our own proprietary Forecast Model, DBEZ Xtrackers MSCI Eurozone will be worth about 57.7 in July 2026. The stock is currently trading at 51.21. This means that the stock has a potential upside of +12.61%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 57.7 12.6%